Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019042168) COMBINED DRUG FOR TREATING TUMORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/042168 International Application No.: PCT/CN2018/101169
Publication Date: 07.03.2019 International Filing Date: 17.08.2018
IPC:
A61K 39/395 (2006.01) ,A61K 31/216 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
21
Esters, e.g. nitroglycerine, selenocyanates
215
of carboxylic acids
216
of acids having aromatic rings, e.g. benactizyne, clofibrate
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
四川九章生物科技有限公司 SICHUAN JIUZHANG BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD [CN/CN]; 中国四川省成都市 高新区科园南二路10号 No. 10, Second Keyuan South Road, High-Tech District Chengdu, Sichuan 610041, CN
Inventors:
张洁 ZHANG, Jie; CN
杨华蓉 YANG, Huarong; CN
张梦甜 ZHANG, Mengtian; CN
Agent:
成都高远知识产权代理事务所(普通合伙) GAOYUNG INTELLECTUAL PROPERTY AGENCY (GENERAL PARTNERSHIP); 中国四川省成都市 高新区衣冠庙邮局A-42号信箱 The Yiguanmiao Post Office Box A-42 Hi-Tech Zone Chengdu, Sichuan 610041, CN
Priority Data:
201710752410.528.08.2017CN
Title (EN) COMBINED DRUG FOR TREATING TUMORS
(FR) ASSOCIATION DE MÉDICAMENTS POUR LE TRAITEMENT DE TUMEURS
(ZH) 一种治疗肿瘤的联合用药物
Abstract:
(EN) The present invention provides a combined drug for treating tumors. The combined drug comprises chlorogenic acid and anti-CTLA-4 monoclonal antibodies in preparations having same or different specifications and units, which are administered at the same time or separately, and comprises a pharmaceutically acceptable carrier. In the present invention, the combined use of the chlorogenic acid and the anti-CTLA-4 monoclonal antibodies can generate a synergistic effect, can effectively reduce toxic and side effects of the anti-CTLA-4 antibodies, can alleviate damages of organisms caused after only the anti-CTLA-4 antibodies is used, and has good clinical application prospects.
(FR) La présente invention concerne une association de médicaments pour le traitement de tumeurs. L'association de médicaments comprend de l'acide chlorogénique et des anticorps monoclonaux anti-CTLA-4 dans des préparations et sous des formes unitaires ayant des spécifications identiques ou différentes, qui sont administrées conjointement ou séparément, et comprend un véhicule pharmaceutiquement acceptable. Dans la présente invention, l'utilisation combinée de l'acide chlorogénique et des anticorps monoclonaux anti-CTLA-4 peut générer un effet synergique, réduire efficacement les effets toxiques et secondaires des anticorps anti-CTLA-4, atténuer les dommages occasionnés aux organismes provoqués après que seuls les anticorps anti-CTLA-4 sont utilisés, et offre de bonnes perspectives d'application clinique.
(ZH) 本发明提供了一种治疗肿瘤的联合用药物,它含有相同或不同规格单位制剂的用于同时或者分别给药的绿原酸与抗CTLA-4单克隆抗体,以及药学上可接受的载体。本发明绿原酸与抗CTLA-4单克隆抗体的联合使用可以发挥协同增效的作用,有效降低抗CTLA-4抗体的毒副作用,缓解单用抗CTLA-4抗体后产生的机体损伤,临床应用前景良好。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)